EGFR and non-small cell lung carcinoma: Nevertheless, the implementation of STK11 mutations as a routine biomarker in NSCLC, in addition to the current mandatory or recommended therapeutic targets (EGFR, ALK, ROS1, BRAF, NTRK, PDL-1, RET, MET and HER2), remains controversial and is not performed in daily practice [58].